Co-Correspondence:
Thomas Eiwegger, MD
Department of Pediatric and Adolescent Medicine, University Hospital St.
Pölten, Dunant-Platz 1, 3100 St. Pölten, Austria, Email:
thomas.eiwegger@stpoelten.lknoe.at, Tel.: +43 2742-9004-11740
Christian Wadsack, PhD
Department of Obstetrics and Gynecology, Medical University of Graz,
Auenbruggerplatz 14, 8036 Graz, Austria, Email:
christian.wadsack@medunigraz.at, Tel.: +43 316-385-81074
Conflicts of Interest: AK, BH, JSL, BP, KS, and CW have nothing
to disclose. ZS holds advisory board roles for Nutricia/Danone, Aimmune
and Sanofi. TE reports to act as local PI for company sponsored trials
by DBV and sub-investigator for Regeneron, holds grants from Innovation
Fund Denmark, CIHR outside the submitted work. He is Co-Investigator or
scientific lead in three investigator-initiated oral immunotherapy
trials supported by the Food Allergy and Anaphylaxis Program SickKids
and serves as an associate editor for Allergy. He/his lab received
unconditional/in-kind contributions from Macro Array Diagnostics and an
unrestricted grant from ALK. He holds advisory board roles for ALK,
Nutricia/Danone and Aimmune.
Financial support: This work was supported by The Hospital for
Sick Children (Food Allergy and Anaphylaxis Program, start-up funds by
the SickKids Research Institute and the Department of Pediatrics,
Restracomp Graduate Scholarship to AK), and an Ontario Graduate
Scholarship from the Province of Ontario to AK.
Statement of Author Contribution: AK, BH, JSL, and KS
contributed to data acquisition. TE, BH and CW contributed to
experimental designs. AK, BH, JSL, BF, KS, CW, ZS, and TE contributed to
data interpretation and preparation of the manuscript. The final version
of the manuscript was approved by all authors.
Keywords : omalizumab, placental transport, ex vivoplacental perfusion system, peanut allergy, basophil activation test
Abbreviations : FcRn; neonatal Fc receptors; BAT, basophil
activation test; Oma, omalizumab
Word Count: 529